Patients aged 60 years and older with essential hypertension were treated with an angiotensinconverting enzyme inhibitor (ACE-I), delapril (Adecut) or a long-acting calcium (Ca)-antagonist, manidipine (Calslot) for 3 years. The incidences of cardiovascular events as well as drug-related side effects were compared between the two groups to investigate whether both classes of antihypertensive drugs are beneficial in elderly hypertensive patients. There were no significant differences in characteristics of patients between the two intervention groups, except for slightly lower blood pressure (P ‫؍‬ .08) in the Ca-antagonist group at the initiation of the study. There were no significant differences in total death between the two groups. Cardiovascular events (both fatal and nonfatal) were noted in 34 of 699 patients (22.5/ 1000 patient-years) in the ACE-I group and 50 of 1049 patients (19.7/1000 patient-years) in the Caantagonist group, with no significant difference found between the two groups. The correlation between cardiovascular incidence and the blood pressure attained during treatment showed a Jshaped phenomenon and suggests that an excessive reduction less than 120 mm Hg in systolic blood pressure (SBP) is unnecessary and may be harmful in certain cases. Side effects were more frequent in the ACE-I group than in the Caantagonist group (P ‫؍‬ .01). Cough was the major adverse event, occurring in 5.0% of patients in the ACE-I group. In conclusion, the study indicates that both ACE-I (delapril) and Ca-antagonist (manidipine) were equally beneficial for reducing cardiovascular morbidity and mortality in elderly hypertensive patients. However, tolerability of ACE-I was lower due to the adverse event of coughing. Am J Hypertens 2000;13:461-467
on Long-term Antihypertensive Therapy) Study 6, 7 was the first prospective open trial conducted in Japan to compare the ACE-I delapril with Ca-antagonists in hypertensive subjects for 1 year, and suggested a lower incidence of cerebrovascular events in the ACE-I group than in the Ca-antagonists group on an intention-to-treat basis. 7 The present prospective open clinical trial, PATE-Hypertension (Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension) Study was conducted to compare long-term outcomes in the elderly patients with essential hypertension taking an ACE-I, delapril (Adecut) or a long-acting Ca-antagonist, manidipine (Calslot) monotherapy for 3 years to investigate which class of antihypertensive drug holds a therapeutic advantage in treating elderly hypertensive patients.
MATERIALS AND METHODS
Only patients of ages 60 years and older, with essential hypertension, who had no major complications of recent onset (within 6 months), and who regularly visited the outpatient clinics of the participating physicians, were enrolled in this study. Physicians participating in this study registered the patients who had responded to either delapril or manidipine treatment for at least 8 weeks and showed adequate tolerance under the physician's own judgment. The registered patients were followed-up for as long as 3 years. Informed consent was obtained from each patient before enrollment. This study was conducted between April 1994 and March 1998, and the mean follow-up time was 28.4 months.
Treatment was commenced at the approved recommended dose by monotherapy, ie, 15 to 60 mg delapril twice daily and 5 to 20 mg manidipine once daily. If sufficient blood pressure reduction (by the physician's definition) was not obtained by monotherapy, other antihypertensive agents were added. If necessary, the dose was reduced or treatment was discontinued in the patients who developed side effects. Delapril, a nonsulfhydryl ACE-I, which has an indanylglycine moiety differing from the proline moiety in captopril or enalapril, is an esterified prodrug. 8 Manidipine is a long-acting dihydropyridine-type calcium antagonist, in which structure diphenylmethyl-piperazinyl moiety is introduced to potentiate vascular selectivity and receptor-binding capacity. 9, 10 The developments of any new symptoms or complications were assessed in consultation with the physicians and reported annually along with the records of blood pressure and pulse rate. The time of onset, nature, treatment, course, and relationship to the treatment drugs were determined for any events and symptoms that developed. Laboratory examinations were performed before and after each year of treatment or on withdrawal. Any new symptoms that developed during treatment were defined as side effects, unless the relationship to the treatment was clearly ruled out.
The primary endpoint of this study was the incidence of cardiovascular morbidity and mortality. Relations between these incidences and the blood pressure attained were also analyzed.
2 statistics were performed to detect differences of major parameters in this study. A t test was applied for baseline comparisons of patients' characteristics. The paired t test was used for comparison of the blood pressure reached between the two groups. P values Ͻ .05 were considered as statistically significant. For the secondary endpoint, survival analyses 11 of cardiovascular and cancer mortality were based on the log-rank test, and risk reductions of each mortality were based on MantelHaenszel adjusted (for age category) relative to risk estimates.
RESULTS

Enrollment and Study Population
A total of 1834 patients were enrolled; 86 cases were excluded because of protocol violation and 1748 cases (95.3%) were analyzed. There were 699 cases included in the ACE-I group and 1049 included in the Ca-antagonist group. Patient Background Table 1 shows the clinical characteristics of the two groups of patients at study entry. Systolic blood pressure (SBP) of the Ca-antagonist group was insignificantly (P ϭ .08) lower than the ACE-I group. There were more female subjects in both groups and the female/male ratio was slightly higher in the ACE-I group (P ϭ .04). No difference was detected between the two groups with respect to other cardiovascular risk factors, such as diabetes mellitus, hyperlipidemia, and concomitant cardiovascular diseases.
Blood Pressure Reduction
Six-hundred and eightytwo patients (97.6%) in the ACE-I group and 1017 patients (96.9%) in the Ca-antagonist group were treated with monotherapy (not significant between the two groups, P ϭ .44). Thus, almost all patients were treated with monotherapy. The blood pressure was decreased significantly after 1 year of treatment for both groups (ACE-I group: 144 Ϯ13/ 80 Ϯ 8 mm Hg; Ca-antagonist group: 141 Ϯ 12/ 79 Ϯ 9 mm Hg), and continued to decrease in the ACE-I group, while it remained at the same level thereafter in the Ca-antagonist group. Final blood pressures were 142 Ϯ 12/ 80 Ϯ 8 mm Hg and 141 Ϯ 12/ 78 Ϯ 9 mm Hg in the ACE-I and Ca-antagonist groups, respectively, and there was no significant difference between the two groups.
Cardiovascular Morbidity and Mortality
Incidences of cardiovascular events are summarized in Table 2 .
Cardiovascular events occurred in 34 patients (22.5/ 1000 patient-years) and in 50 patients (19.7/1000 patient-years) in the ACE-I and Ca-antagonist groups, respectively (NS). Cerebrovascular events occurred in 14 patients (9.3/1000 patient-years) in the ACE-I group and in 23 patients (9.1/1000 patient-years) in the Ca-antagonist group (NS). However, cardiac events occurred in 20 patients (13.3/1000 patientyears) in the ACE-I group and in 25 patients (9.9/1000 patient-years) in the Ca-antagonist group (NS). Other cardiovascular events (aortic aneurysm) occurred in two patients were in the Ca-antagonist group only. Seven patients in the ACE-I group and 10 patients in the Ca-antagonist group died of cardiovascular events during the study (NS). In the ACE-I group, there were four deaths due to cardiac events and three deaths due to cerebrovascular events. As for the Ca-antagonist group, there were three deaths due to cardiac events, one death due to rupture of aortic aneurysm, and six deaths attributable to cerebrovascular events. There was no significant difference between the ratios of the two groups. Figure 1 shows the incidence of cardiac events as a function of SBP and diastolic blood pressure (DBP) reached. Patients measuring between 130 and 139 mm Hg in SBP showed significantly lower incidence of cardiac events (P Ͻ .01) than patients with observed SBP less than 120 mm Hg in both classes of drugs. No relation was observed between the incidences of cardiac events and DBP reached in both groups. Figure 2 shows the incidence of cerebrovascular events as a function of SBP and DBP reached. Patients measuring between 75 to 79 mm Hg in DBP showed significantly lower incidence of cerebrovascular events (P Ͻ .01) than patients measuring 90 mm Hg or higher in DBP in the Ca-antagonist group; however, there was no significant relation between the incidence of cerebrovascular events and DBP reached in the ACE-I group. (Table 3 ) Cancer events occurred in 20 patients in the ACE-I group and 23 patients in the Ca-antagonist group (NS). Four patients in the ACE-I group and eight patients in the Ca-antagonist group died of malignancy during the study (NS).
Cancer Morbidity and Mortality
Total Deaths and Survival Analyses
During the course of the study, death occurred in 11 patients in the ACE-I group and 18 patients in the Ca-antagonist group (NS). Survival analyses of cardiovascular and cancer mortality are summarized in Table 4 . Statistical treatments by each complication show that there were no significant differences between the two groups.
Side Effects A total of 94 symptoms were identified as side effects; 57 patients (8.2%) in the ACE-I group and 37 patients (3.5%) in the Ca-antagonist group experienced side effects (P ϭ .01). Cough was the major adverse event in the ACE-I group, and was reported in 35 patients (5.0%). Treatment was withdrawn due to side effects in 35 patients (5.0%) in the ACE-I group and 13 patients (1.2%) in the Ca-antagonist group (P Ͻ .01). The major reason for withdrawal was due to cough in the ACE-I group. During the study, an abnormal clinical laboratory change was observed in 30 patients (4.3%) in the ACE-I group and in 52 patients (5.0%) in the Ca-antagonist group.
DISCUSSION
Due to the inherent nature of the trial being opencomparative in design, interpretations of the data analyses in the present study have some limitations. However, compared with the GLANT Study, which was virtually of the same design (except for the entry criteria and the ages of enrolled patients), the PATEHypertension Study was conducted with an equivalent number of participants who were 60 years or older, and patient follow-up was as long as 3 years by general practitioners. Thus, this study should provide valuable information on the daily practice for elderly hypertensive patients in Japan. Additionally, it was possible to obtain a clear outcome because the study was conducted with either manidipine or delapril monotherapy (almost 97% in both groups). In the GLANT Study, more cerebrovascular events were observed in the Ca-antagonist group than in the ACE-I group. 7 However, in the present study, there were no significant differences in the incidence of cardiovascular events, cerebrovascular events, and cardiac events between the two groups. The results support the conclusion by Alderman et al 12 that long-acting Ca-antagonists have little basis to be associated with the increase of a risk of coronary event.
The present results are compared with other largescale intervention trials performed in elderly hyper- tensive patients in Table 5 in terms of cardiovascular events per 1000 patient-years. The incidences of cardiovascular events, 22.5/1000 patient-years in the ACE-I group and 19.7/1000 patient-years in the Caantagonist group, are shown to be lower than those in the EWPHE (74.2), 13 SHEP (49.3), 14 and STOP-Hypertension trials (33.5), 15 and to be similar to the finding in the MRCII (21.0) 16 and the Syst-Eur study (23.3). 3 These findings suggest that both ACE-I and Ca-antagonists are beneficial in elderly hypertensive patients for long-term therapy and there were no differences in efficacy for reductions in cardiovascular morbidity and mortality between the two groups. The effectiveness of Ca-antagonists in elderly hypertensive patients has been demonstrated in many trials, such as SystEur, 3 Syst-China, 16 and STONE, 17 conducted in both European countries and China, and the present results show the benefits of Ca-antagonists in Japanese patients as well. It is well known that ACE-I are effective to reduce blood pressure in elderly patients without any special concern for age. 19 There were no differences in the blood pressure reached at the end of the study between the ACE-I and Ca-antagonist groups. Nonetheless, the GLANT Study showed that an ACE-I was more preventive of cardiovascular events, especially cerebrovascular events, than Ca-antagonists. In this study, both treatments were shown to have similar rates of prevention and such trends as shown in the GLANT Study were not found. Thus, ACE-I are equally effective for reducing cardiovascular events as Ca-antagonists in elderly hypertensive patients. The 
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present study differs from the GLANT study in several points. The GLANT Study is not a study specific for elderly patients. The mean age of the subjects in the GLANT Study was younger (mean 60 years) than in this trial. The duration of observation was only 1 year in the GLANT Study; and the agents used in the GLANT Study were delapril versus nonspecific Caantagonists. They were delapril versus manidipne in the present study. These may be retated to the difference in the results between the GLANT study and the present study.
The existence of J-shaped phenomena is a point of discussion in hypertension therapy in the elderly. 20, 21 In a comparison of the relations between the incidence of cardiac events and blood pressure reached after medication in this study, there was a significant relation between SBP and cardiac events in both the ACE-I and Ca-antagonist groups, and we observed a statistically higher incidence of cardiac events when patients recorded 120 mm Hg in SBP. There were no significant relations between the incidence of cardiac events and DBP. On the other hand, a J-shaped phenomenon was not observed clearly in the relations between the incidence of cerebrovascular events and blood pressure reached. The cardiac event data of the present study suggest that an excessive reduction of blood pressure to less than 120 mm Hg is unnecessary or may be harmful in certain cases in elderly hypertensive patients.
There were no significant differences in total death, survival analyses, and the incidence of cancer between the two groups. It was currently reported that the incidence of cancer was reduced with ACE-I 22 and increased by the Ca-antagonist. 23 However, neither finding was observed in the present study. In terms of side effects, the incidence of side effects, cough in particular, was much higher in the ACE-I group than in the Ca-antagonist group, and the withdrawal rate was significantly less in the Ca-antagonist group. This indicates that tolerability is higher with the Ca-antagonist than the ACE-I. This may be a plausible explanation for why Ca-antagonists are more often prescribed for geriatric hypertension in Japan.. 24, 25 In conclusion, both ACE-I and a Ca-antagonist were similarly effective for elderly hypertensive patients, and both equally reduced the incidence of cardiovascular events. A J-shaped phenomenon was observed in the relation between SBP and the incidence of cardiac events, and it is suggested that an excessive reduction of less than 120 mm Hg is unnecessary and may be harmful in certain cases. There were no significant differences of the incidence of cancer between the two groups. Side effects, such as a higher incidence of cough, were observed more in the ACE-I group and the Ca-antagonist, manidipine was more tolerable than the ACE-I type therapy in elderly hypertensive patients.
